Sugi Predict

Sugi Predict / Compounds / SCHEMBL7839736

SCHEMBL7839736

SCHEMBL7839736

O=C(O)CCNC(=O)CCCCC1CCSS1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 10/20 0.72
▸ HSD17B10 Q99714 2/20 0.72
▸ KMT2A Q03164 2/20 0.72
▸ TARDBP Q13148 2/20 0.72
▸ CYP2C9 P11712 1/20 0.72
▸ MEN1 O00255 1/20 0.72
▸ NR1I2 O75469 1/20 0.72
▸ ALDH1A1 P00352 1/20 0.72
▸ LMNA P02545 1/20 0.72
▸ POLB P06746 1/20 0.72
▸ THRB P10828 1/20 0.72
▸ TSHR P16473 1/20 0.72
▸ APEX1 P27695 1/20 0.72
▸ RECQL P46063 1/20 0.72
▸ BLM P54132 1/20 0.72
▸ PMP22 Q01453 1/20 0.72
▸ TDP1 Q9NUW8 1/20 0.72
▸ SAE1 Q9UBE0 1/20 0.72
▸ UBA2 Q9UBT2 1/20 0.72
▸ L3MBTL1 Q9Y468 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27509654 1.00 ACHE (0.72) ACHEHSD17B10KMT2ATARDBPCYP2C9
SCHEMBL8521628 1.00 ACHE (0.72) ACHEHSD17B10KMT2ATARDBPCYP2C9
SCHEMBL17265769 0.93 ACHE (0.75) ACHEHSD17B10KMT2ATARDBPCYP2C9
SCHEMBL7839737 0.93 ACHE (0.75) ACHEHSD17B10KMT2ATARDBPCYP2C9
SCHEMBL7841655 0.93 ACHE (0.75) ACHEHSD17B10KMT2ATARDBPCYP2C9
SCHEMBL13834757 0.90 CA12 (0.74) ACHEHSD17B10KMT2ATARDBPCYP2C9
SCHEMBL7838460 0.89 ACHE (0.68) ACHEHSD17B10KMT2ATARDBPCYP2C9
SCHEMBL17265767 0.88 HSD17B10 (0.71) ACHEHSD17B10KMT2ATARDBPCYP2C9
SCHEMBL7844379 0.88 HSD17B10 (0.71) ACHEHSD17B10KMT2ATARDBPCYP2C9
SCHEMBL7832225 0.87 ACHE (0.66) ACHEHSD17B10KMT2ATARDBPCYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4282411-A1 LIPOYL-GLU-ALA FOR THE TREATMENT OF NEURODEGENERATIVE DAMAGE CAUSED BY TRAUMATIC BRAIN INJURY Ischemix LLC (US) 2023-11-29 — — EP disclosed
US-11213509-B2 Compositions and methods for treating traumatic brain injury Ischemix, LLC (US) 2022-01-04 — — US disclosed
US-20200352904-A1 Compositions And Methods For Treating Traumatic Brain Injury ISCHEMIX LLC 2020-11-12 — — US disclosed
US-10744115-B2 Compositions and methods for treating traumatic brain injury ISCHEMIX LLC (US) 2020-08-18 — — US disclosed
EP-2640423-B1 LIPOYL COMPOUNDS AND THEIR USE FOR TREATING ISCHEMIC INJURY ISCHEMIX LLC (US) 2017-07-26 — — EP disclosed
US-9359325-B2 Lipoyl compounds and methods for treating ischemic injury ISCHEMIX LLC (US) 2016-06-07 — — US disclosed
US-9359325-B2 Lipoyl compounds and methods for treating ischemic injury ISCHEMIX LLC (US) 2016-06-07 — — US disclosed
US-20150329519-A1 Formulations Comprising Lipoyl Compounds Ischemix, LLC 2015-11-19 — — US disclosed
US-20150329519-A1 Formulations Comprising Lipoyl Compounds Ischemix, LLC 2015-11-19 — — US disclosed
WO-2015174948-A1 FORMULATIONS COMPRISING LIPOYL COMPOUNDS Ischemix, LLC (US) 2015-11-19 — — WO disclosed
US-20150065564-A1 LIPOYL COMPOUNDS AND METHODS FOR TREATING ISCHEMIC INJURY ISCHEMIX LLC 2015-03-05 — — US disclosed
US-8815937-B2 Lipoyl compounds and their use for treating ischemic injury ISCHEMIX LLC (US) 2014-08-26 — — US disclosed
US-8815937-B2 Lipoyl compounds and their use for treating ischemic injury ISCHEMIX LLC (US) 2014-08-26 — — US disclosed
US-20130237483-A1 Lipoyl Compounds And Their Use for Treating Ischemic Injury ISCHEMIX LLC 2013-09-12 — — US disclosed
US-20130237483-A1 Lipoyl Compounds And Their Use for Treating Ischemic Injury ISCHEMIX LLC 2013-09-12 — — US disclosed
WO-2012067947-A1 LIPOYL COMPOUNDS AND THEIR USE FOR TREATING ISCHEMIC INJURY ISCHEMIX LLC (US) 2012-05-24 — — WO disclosed
US-6313164-B1 TO ENHANCE THE ACTIVITY OF GLUTATHIONE RECLUCTASE; FOR THERAPY AND PROPHYLAXIS OF CARTARACTS SANKYO COMPANY, LIMITED (JP) 2001-11-06 — — US disclosed
EP-1070710-A2 Dithiolan derivatives, their preparation and their therapeutic effect Sankyo Company Limited (JP) 2001-01-24 — — EP disclosed
US-6013663-A CATARACT THERAPY OR PREVENTION SANKYO COMPANY, LIMITED (JP) 2000-01-11 — — US disclosed
EP-0869126-A1 Dithiolan derivatives, their preparation and their therapeutic effect Sankyo Company Limited (JP) 1998-10-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11213509-B2 Compositions and methods for treating traumatic brain injury BDNF, NLN, FABP7 ACHE 8/4885HSD17B10 2210/4885KMT2A 1906/4885
US-20150065564-A1 LIPOYL COMPOUNDS AND METHODS FOR TREATING ISCHEMIC INJURY CPT1A, LIPC, LIPG ACHE 1638/4885HSD17B10 311/4885KMT2A 3866/4885
US-20200352904-A1 Compositions And Methods For Treating Traumatic Brain Injury BDNF, NLN, FABP7 ACHE 8/4885HSD17B10 2210/4885KMT2A 1906/4885
US-10744115-B2 Compositions and methods for treating traumatic brain injury BDNF, NLN, FABP7 ACHE 8/4885HSD17B10 2210/4885KMT2A 1906/4885
US-20130237483-A1 Lipoyl Compounds And Their Use for Treating Ischemic Injury CPT1A, LIPG, LIPC ACHE 2328/4885HSD17B10 397/4885KMT2A 4363/4885
US-20150329519-A1 Formulations Comprising Lipoyl Compounds LIPC, LIPA, DLST ACHE 4186/4885HSD17B10 1428/4885KMT2A 1808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.